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Abstract
Purpose: multiple myeloma is considered an incurable hematologic cancer but a subset of patients can achieve long-
term remissions and survival. The present study examines the clinical features of long-term survival as it correlates to
depth of disease response. Patients & Methods: this was a multi-institutional, international, retrospective analysis of
high-dose melphalan-autologous stem cell transplant (HDM-ASCT) eligible MM patients included in clinical trials.
Clinical variable and survival data were collected from 7291 MM patients from Czech Republic, France, Germany, Italy,
Korea, Spain, the Nordic Myeloma Study Group and the United States. Kaplan–Meier curves were used to assess
progression-free survival (PFS) and overall survival (OS). Relative survival (RS) and statistical cure fractions (CF) were
computed for all patients with available data. Results: achieving CR at 1 year was associated with superior PFS (median
PFS 3.3 years vs. 2.6 years, p < 0.0001) as well as OS (median OS 8.5 years vs. 6.3 years, p < 0.0001). Clinical variables at
diagnosis associated with 5-year survival and 10-year survival were compared with those associated with 2-year death.
In multivariate analysis, age over 65 years (OR 1.87, p= 0.002), IgA Isotype (OR 1.53, p= 0.004), low albumin < 3.5 g/dL
(OR= 1.36, p= 0.023), elevated beta 2 microglobulin ≥ 3.5 mg/dL (OR 1.86, p < 0.001), serum creatinine levels ≥ 2 mg/
dL (OR 1.77, p= 0.005), hemoglobin levels < 10 g/dL (OR 1.55, p= 0.003), and platelet count < 150k/μL (OR 2.26, p <
0.001) appeared to be negatively associated with 10-year survival. The relative survival for the cohort was ~0.9, and the
statistical cure fraction was 14.3%. Conclusions: these data identify CR as an important predictor of long-term survival
for HDM-ASCT eligible MM patients. They also identify clinical variables reflective of higher disease burden as poor
prognostic markers for long-term survival.
Introduction
The last decade has witnessed major progress in clinical
outcomes in multiple myeloma (MM), attributable to the
introduction of several novel agents which, when
combined with either each other or conventional cyto-
toxic drugs, have imparted a high frequency of complete
responses (CR)1–4. This is especially true for younger and
high-dose melphalan-autologous stem cell transplant
(HDM-ASCT) eligible patients where pre-transplant
induction therapy is able to provide > 60% rates of very
good partial response or better. HDM-ASCT further
deepens the response and results in ~CR rates. Several
prospective studies have reported strong correlation
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between depth of response (achieving CR) and
progression-free survival (PFS) and overall survival (OS)
in the era of novel agents. There is also a clear recognition
that patients achieving CR may have variable PFS/OS5,
perhaps dictated by differences in disease biology and
shortcomings of the current response criteria. Minimal
residual disease (MRD) testing, by either flow or DNA
sequencing, has demonstrated that CR patients may have
residual disease (MRD positive) putting them at risk for
early relapse6.
These advances have re-ignited the debate on possible
functional curability of a subset MM patients5. The
Spanish Myeloma group recently reported the strong
correlation of depth of response to higher likelihood of
long-term PFS/OS (12-year PFS was 28% in CR, 19% in
nCR, 10% in VGPR and 11% in PR groups; 12-year OS was
35% in CR, 22% in nCR, 16% in VGPR and 16% in PR
groups) among 344 post HDM-ASCT patients followed
for a median of nearly 13 years7. The current study is a
collaborative effort by the Internal Myeloma Working
Group to closely examine the clinical predictors of long-
term survival in MM (>10 yr) in terms of their presenting
features, quality of response and management in order to
guide therapeutic investigations aimed at long-term dis-
ease control.
Patients and methods
Patient population
A total of 7291 patients with survival data were con-
sidered for the analysis, age limit up to 75 years. These
patients come from the following nations: Czech Repub-
lic, France, Germany, Italy, South Korea, Spain, the Nor-
dic Myeloma Study Group (Sweden, Denmark, Norway),
and the United States. Tables comparing patient char-
acteristics for several key variables for patients meeting
specified characteristics are included, as are tables show-
ing a summary of available data by country (Supplemental
Table 3). It is important to note that over 90% of the
patients in the dataset were from the pre-novel therapy
induction era and ~10% did received thalidomide as part
of their upfront therapy (Total Therapy 2 thalidomide
arm, GMMG-HD3 thalidomide arm and BO2002).
Statistical analysis
Kaplan–Meier curves8 were used to assess OS, PFS, and
CR duration (where applicable). Relative survival (RS)9
was computed for all patients with available data. The goal
of RS analysis is to compare the survival of a cohort with a
certain disease to the survival of the general population
with similar characteristics to that cohort. We estimate
the ratio of observed survival amongst patients with a
certain condition to expected survival in a comparable
population with comparable characteristics (such as
nationality, age, and sex) to those patients. In this analysis,
we consider a patient’s nationality, age at enrollment, and
sex (where available), and obtained expected survival
estimates from life tables for a person with those char-
acteristics starting in the year of the patient’s enrollment
(note: where sex data not available, we use data from life
tables estimated for nationality and age which did not
adjust for sex). Here, we provide estimates for RS for the
IMWG data overall and by individual country, with point
estimates at each 1-year interval from start of therapy, and
a 95% confidence band for the RS.
Berkson–Gage cure modeling10 was performed for a
proportion of patients who represent a “cure proportion;”
in other words, these patients are said to have survival
according to the normal survival rates for a person of that
age/sex/nationality. The figures in the manuscript repre-
sent survival curves, where survival is the survival for the
“cure proportion” plus the survival for the remainder of
patients.
Results
The OS, PFS, and CR duration separated by each
country is presented in the supplemental files (Supple-
mental Figure 1a-d). For the combined dataset analyses,
the OS and PFS were compared between patients who
achieved CR landmarked at 1 year after diagnosis (Fig. 1)
to examine the effects of depth of response on outcome.
Patients who achieved CR had a superior PFS (median
PFS 3.3 years vs. 2.6 years, p < 0.0001); this effect was most
pronounced for the patients who received thalidomide
(the only novel agent used in dataset) with higher CR rates
observed and median PFS of 6 years for those who
achieved CR (Supplemental Figure 1e/f). The benefit was
also seen in terms of OS for the whole group (median OS
8.5 years vs. 6.3 years, p < 0.0001). Patients who had
albumin < 3.5 g/dL (p= 0.002) or an IgG isotype (p <
0.001) were less likely to achieve a CR at the 1-year
landmark (Table 1). Age over 65 years was not associated
with inability to achieve CR in this dataset. We further
examined clinical variables associated with sustained CR
for 3 years and 5 years in subset of patients where these
data were available (Supplemental Tables 6, 7) using
logistic regression. These analyses were not very infor-
mative, as only IgA isotype, light chain only disease and
BMPC > 30% featured with statistical significance in
multivariate analyses for both time points.
We also examined the clinical variables associated with
10-year survival compared with 2-year death (Table 2). In
a univariate model, age ≤ 65 years (OR 2.24, p < 0.001),
normal albumin (OR 2.01, p < 0.001), low beta 2 micro-
globulin ≤ 3.5 mg/dl (OR 3.51, p < 0.001), serum creati-
nine levels ≤ 2mg/dL (OR 3.73, p < 0.001), hemoglobin
levels ≥ 10 g/dL (OR 2.98, p < 0.001), platelet count ≥
150k/μL (OR 3.94, p < 0.001), normal serum LDH levels
(OR 2.78, p < 0.001), no cytogenetic abnormality (OR 3.21,
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p < 0.001), BM plasmacytosis < 30% (OR 2.31, p < 0.001),
and ISS stage I or II (OR 3.59, p < 0.001) appeared to be
positively associated with 10-year survival. In multivariate
analysis, age ≤ 65 years (OR 1.87, p= 0.002), non-IgA
Isotype (OR 1.53, p= 0.004), normal albumin < 3.5 g/dL
(OR= 1.36, p= 0.023), low beta 2 microglobulin ≤
3.5 mg/dl (OR 1.86, p < 0.001), serum creatinine levels <
2 mg/dL (OR 1.77, p= 0.005), hemoglobin levels ≥ 10 g/
dL (OR 1.55, p= 0.003), and platelet count ≥ 150k/μL (OR
2.26, p < 0.001) appeared to positively associated with 10-
year survival. Interestingly, cytogenetic abnormalities did
not feature in multivariate analysis.
We then examined the RS of the whole patient cohort to
matched general population. We note that RS was
between 0.8 and 0.95 for all countries during the first
several years of therapy, with RS for all countries
Fig. 1 Overall survival and progression-free survival at 1 year by CR status
Table 1 Patient characteristics by CR Indicator at 1 year
Factor All patients Less than CR within first
year
CR within first year P-value Percent of patients w/
data
Age at registration>= 65 yr 258/3867 (7%) 194/2906 (7%) 64/961 (7%) 0.986 258/3867 (7%)
IgA 735/3086 (24%) 499/2326 (21%) 236/760 (31%) < 0.001 735/3086 (24%)
IgG 1868/3086 (61%) 1549/2326 (67%) 319/760 (42%) < 0.001 1868/3086 (61%)
Female 1380/3286 (42%) 1018/2442 (42%) 362/844 (43%) 0.542 1380/3286 (42%)
Albumin < 3.5 g/dL 1041/3443 (30%) 819/2590 (32%) 222/853 (26%) 0.002 1041/3443 (30%)
B2M >= 3.5 mg/L 1517/3681 (41%) 1126/2753 (41%) 391/928 (42%) 0.510 1517/3681 (41%)
B2M > 5.5 mg/L 708/3681 (19%) 517/2753 (19%) 191/928 (21%) 0.231 708/3681 (19%)
Creatinine >= 2 mg/dL 397/3802 (10%) 282/2852 (10%) 115/950 (12%) 0.056 397/3802 (10%)
HGB < 10 g/dL 1280/3785 (34%) 973/2842 (34%) 307/943 (33%) 0.343 1280/3785 (34%)
LDH > Upper Limit Normal 403/2244 (18%) 288/1740 (17%) 115/504 (23%) 0.002 403/2244 (18%)
Platelet Count < 150 × 10^9/L 635/3758 (17%) 454/2838 (16%) 181/920 (20%) 0.011 635/3758 (17%)
Any clonal abnormality by
cytogenetics
322/1256 (26%) 209/822 (25%) 113/434 (26%) 0.814 322/1256 (26%)
BMPC >= 30% 1986/3077 (65%) 1472/2260 (65%) 514/817 (63%) 0.257 1986/3077 (65%)
ISS Stage 1 1860/2645 (70%) 1351/1949 (69%) 509/696 (73%) 0.057 1860/2645 (70%)
ISS Stage 2 1505/3302 (46%) 1121/2475 (45%) 384/827 (46%) 0.569 1505/3302 (46%)
ISS Stage 3 1242/3388 (37%) 954/2542 (38%) 288/846 (34%) 0.067 1242/3388 (37%)
n/N (%): n—Number with factor, N—Number with valid data for factor
ND No valid observations for factor
*P-value from Fisher’s exact test, otherwise chi-squared test. P-values represent a comparison between groups, not against the overall population
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combined close to 0.9, the ISS III patients had a lower RS
compared to ISS I/II patients (Fig. 2a). Cumulative RS
plots by ISS staging also shows a decline over time in the
ISS III patients’ probability of achieving RS similar to
matched population (Fig. 2b). The RS curves were also
examined by country (Supplemental Figures 3a-h) and
showed similar trends to the overall dataset. The statis-
tical cure fraction for the whole group appears to be 14.3%
(Fig. 2c), which signifies the overall proportion of MM
patients in this cohort who were able to achieve or exceed
expected survival compared to matched general
population.
Discussion
There have been several large population based studies
that have highlighted the trends of improvements in MM
survival and outcomes11–14. Whereas we can attribute this
success to the therapeutic success of new drug classes, it
also clear that not every MM patient achieves the same
depth of response. We also appreciate that despite
achieving a good depth of by current IMWG criteria, a
proportion of MM patients remains at a high risk of
relapse within the first 2 years of diagnosis15. It has also
been observed that, despite not achieving CR, patients
with documented antecedent smoldering course and
Table 2 Logistic regression, 10-year survival vs. 2-year death
Factors differentiating 10-year survival vs. 2-year death
Variable N Survival less than 2 years Survival more than 10 years OR (95% CI) P-value
Univariate
Age at registration >= 65 yr 2374 163/214 (76%) 1271/2160 (59%) 2.24 (1.61, 3.10) < 0.001
IgA 1878 306/463 (66%) 785/1415 (55%) 1.56 (1.26, 1.95) < 0.001
IgG 1878 580/1080 (54%) 511/798 (64%) 0.65 (0.54, 0.79) < 0.001
Female 1918 493/827 (60%) 685/1091 (63%) 0.87 (0.73, 1.05) 0.157
Albumin < 3.5 g/dL 2206 559/808 (69%) 737/1398 (53%) 2.01 (1.68, 2.42) < 0.001
B2M >= 3.5 mg/L 2208 833/1123 (74%) 488/1085 (45%) 3.51 (2.94, 4.20) < 0.001
B2M > 5.5 mg/L 2208 501/630 (80%) 820/1578 (52%) 3.59 (2.89, 4.46) < 0.001
Creatinine >= 2 mg/dL 2320 353/430 (82%) 1042/1890 (55%) 3.73 (2.87, 4.85) < 0.001
HGB < 10 g/dL 2313 678/908 (75%) 699/1405 (50%) 2.98 (2.48, 3.57) < 0.001
LDH > Upper Limit Normal 935 196/260 (75%) 354/675 (52%) 2.78 (2.02, 3.82) < 0.001
Platelet Count < 150 × 10^9/L 2241 364/443 (82%) 969/1798 (54%) 3.94 (3.04, 5.11) < 0.001
Any clonal abnormality by cytogenetics 507 92/145 (63%) 127/362 (35%) 3.21 (2.15, 4.80) < 0.001
BMPC >= 30% 1933 800/1226 (65%) 317/707 (45%) 2.31 (1.91, 2.79) < 0.001
ISS Stage 1 2070 296/761 (39%) 910/1309 (70%) 0.28 (0.23, 0.34) < 0.001
ISS Stage 2 2105 477/756 (63%) 759/1349 (56%) 1.33 (1.11, 1.60) 0.002
ISS Stage 3 2208 501/630 (80%) 820/1578 (52%) 3.59 (2.89, 4.46) < 0.001
Multivariate (stratified by country)
Age at registration >= 65 yr 1230 98/144 (68%) 525/1086 (48%) 1.87 (1.26, 2.79) 0.002
IgA 1230 180/298 (60%) 443/932 (48%) 1.53 (1.15, 2.04) 0.004
Albumin < 3.5 g/dL 1230 294/474 (62%) 329/756 (44%) 1.36 (1.04, 1.78) 0.023
B2M >= 3.5 mg/L 1230 376/569 (66%) 247/661 (37%) 1.86 (1.41, 2.45) < 0.001
Creatinine >= 2 mg/dL 1230 130/174 (75%) 493/1056 (47%) 1.77 (1.18, 2.65) 0.005
HGB < 10 g/dL 1230 288/429 (67%) 335/801 (42%) 1.55 (1.16, 2.06) 0.003
Platelet Count < 150 × 10^9/L 1230 163/218 (75%) 460/1012 (45%) 2.26 (1.59, 3.22) < 0.001
P-value from Wald chi-square test in logistic regression. NS2–Multivariate results not statistically significant at 0.05 level. Univariate p-values reported regardless of
significance. Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level. A multivariate p-value greater than 0.05
indicates variable forced into model with significant variables chosen using stepwise selection
OR odds ratio, 95% CI 95% confidence interval
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those presenting with a MGUS-like gene expression
profiling (GEP) signature can have OS of over 10 years
(75% patients) after HDM-ASCT16. This perhaps explains
the subgroup of PR patients in the Spanish Myeloma
group experience that remain progression free at 12-
years7.
Several next generation sequencing studies in MM17,18
have elegantly demonstrated the heterogeneous nature of
MM, even within the same patient during the course of
disease, when treated sequentially with novel therapies.
These data highlight the genetic chaos that is present
from the very onset of disease and further evolves rapidly
with each relapse so that eventually total resistance to
salvage interventions ensues. We also have to appreciate
that there are perhaps more effective drugs and drug
classes in the clinician’s armamentarium than was avail-
able for MM patients being treated in the 1990s or even
early 2000s. This may mean that the depth of response
after induction therapy may continue to improve over
time, potentially further improving the PFS/OS of biologic
subset who previously achieved PR yet had good long-
term survival.
Cure modeling has been utilized for survival analysis for
over three decades. In general, survival analyses include
censored observations for subjects who are lost to follow-
up or have not experienced and event at the time the
analysis is conducted. Most cure modeling has been done
in pediatric cancer population, where the other causes of
death can be ignored on account of rarity. In case of adult
cancer, there may be subjects who never have disease
recurrence and perhaps have been cured of the disease.
Cure modeling is a special statistical technique which
attempts to capture this subset of patients and several
different techniques such as cure fractions and RS rate
have been described in literature19. To calculate cure
fraction, one has to assume that the disease is cured and
Fig. 2 Relative Survival Analyses (A) Relative survival, ISS Stage III vs. ISS Stage I/II, (B) Cumulative relative survival, ISS Stage III vs. ISS Stage I/II, (C) Cure
fraction for the study population
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that it is difficult to make this technique applicable to the
whole MM population due to competing causes of death
—but perhaps the younger, HDM-ASCT eligible MM
patients may benefit from such an analysis20. In the pre-
sent analysis, we see a cure fraction of 14.37% for the
study population which is impressive; yet we must bear in
mind that this is a select, HDM-ASCT eligible MM
patient population on clinical trials. It is important to
emphasize that, in order to have a mature long-term
follow-up, most patients included in the present study
were treated with conventional agents before the era of
novel drugs.
To adjust for the lack of evidence of cure for individual
patients, a better approach may be looking at “statistical”
or “functional” cure via RS modeling. This latter techni-
que compares the expected survival of a given subjects
with similar characteristics and co-morbidities to the
actual survival as a result of cancer. The expected survival
is readily available through life tables available through
national mortality statistics. For most cancers, it takes
several years before the RS curve reach a plateau. We
observe a similar trend for HDM-ASCT eligible MM
patients in the current analysis, where there is steady rise
in the RS beyond 5 years of diagnosis regardless of ISS
staging.
The present study is the largest cohort of HDM-ASCT
eligible patients that has been collected to interrogate the
clinical predictors of long-term survivors. An important
caveat in the current study is that the dataset includes
HDM-ASCT eligible MM patients enrolled on clinical
trials. Choosing this cohort afforded us completeness of
baseline clinical variables, availability of long-term follow-
up and survival data. We identified achieving CR in the
first year of diagnosis an important landmark as it was
found to be associated with superior PFS and OS. This is
an important finding and underscores the importance of
depth of response as we explore novel regimens for newly
diagnosed MM along with MRD endpoints. Next, the
study identified older age at diagnosis and higher burden
of disease (by BM plasmacytosis, level of anemia and
serum creatinine levels, etc.) adversely affected probability
of long-term survival ( > 10 years) compared with early
death ( < 2 years). Although high risk features such as
elevated serum LDH levels and having any cytogenetics
abnormalities were adverse variables in univariate analy-
sis, they did not feature in multivariate analysis. This
perhaps is a function of having inadequate cytogenetics
information on all the patients in the dataset and reliance
on conventional band karyotyping.
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